These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15373778)

  • 21. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
    Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
    J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The T1796A mutation of the BRAF gene is absent in Spitz nevi.
    Palmedo G; Hantschke M; Rütten A; Mentzel T; Hügel H; Flaig MJ; Yazdi AS; Sander CA; Kutzner H
    J Cutan Pathol; 2004 Mar; 31(3):266-70. PubMed ID: 14984580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure.
    Karram S; Novy M; Saroufim M; Loya A; Taraif S; Houreih MA; Rauscher B; Habib RH; Oberkanins C; Khalifeh I
    Am J Dermatopathol; 2013 Jun; 35(4):412-8. PubMed ID: 23051629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
    Uribe P; Andrade L; Gonzalez S
    J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
    J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions.
    Smalley KS; Herlyn M
    J Invest Dermatol; 2004 Oct; 123(4):xvi-xvii. PubMed ID: 15373800
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
    Takata M; Murata H; Saida T
    Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High BRAF mutation frequency does not characterize all melanocytic tumor types.
    Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
    Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aggressive melanoma in an infant with congenital melanocytic nevus syndrome and multiple, NRAS and BRAF mutation-negative nodules.
    de la Rosa Carrillo D; Vindenes H; Kinsler VA; Rønnestad A; Ringstad G; Müller LO; Tafjord S; Tønseth KA; Kvamme B; Clausen OPF
    Pediatr Dermatol; 2018 Sep; 35(5):e281-e285. PubMed ID: 29999207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
    Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
    Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
    Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
    Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
    J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
    Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
    BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
    Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Genetic Evolution of Melanoma from Precursor Lesions.
    Shain AH; Yeh I; Kovalyshyn I; Sriharan A; Talevich E; Gagnon A; Dummer R; North J; Pincus L; Ruben B; Rickaby W; D'Arrigo C; Robson A; Bastian BC
    N Engl J Med; 2015 Nov; 373(20):1926-36. PubMed ID: 26559571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Increased risk of developing a second primary cutaneous nevus-associated melanoma in patients previously diagnosed with the disease].
    Echeverría B; Botella-Estrada R; Serra-Guillén C; Martorell A; Traves V; Requena C; Sanmartín O; Llombart B; Guillén C; Nagore E
    Actas Dermosifiliogr; 2010 Oct; 101(8):710-6. PubMed ID: 20965014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.